Cardiovascular mortality in chronic renal failure: Hyperphosphatemia, coronary calcification, and the role of phosphate binders

Cleveland Clinic Journal of Medicine

Volumn 69, Issue SUPPL. 3, 2002, Pages

  Fatica, Richard A ^a   Dennis, Vincent W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; PHOSPHATE; PHOSPHATE BINDING AGENT; ACETIC ACID DERIVATIVE; ANTACID AGENT; CALCIUM; CALCIUM ACETATE; POLYALLYLAMINE; POLYAMINE;

ARTERY CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIALYSIS; DISEASE ASSOCIATION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DYSFUNCTION; MORTALITY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; BLOOD; CALCINOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ACETATES; ANTACIDS; CALCINOSIS; CALCIUM; CORONARY ARTERIOSCLEROSIS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PHOSPHATES; POLYAMINES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RISK FACTORS;

EID: 0036048751     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.suppl_3.s21     Document Type: Review

References (26)

1. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38(suppl 1):S26-S29.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-617.
3. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35:1226-1237.
4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon TE, Port FK. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12:2131-2138.
5. Johannes L, Armstrong D. Why some dialysis patients take $12-a-day drug instead of Turns. Wall Street Journal. June 26, 2001:B1.
6. Dennis VW. Phosphate disorders. In: Kokko JP, Tannen RL, eds. Fluids and Electrolytes. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1996:359-419.
7. Hsu CH. Are we mismanaging calcium and phosphate in renal failure? Am J Kidney Dis 1997; 29:641-649.
8. Slatopolsky E, Bricker NS. The role of phosphate restriction in prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973; 4:141-145.
9. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 2001; 37(suppl 2):S54-S57.
10. Drueke TB. Control of secondary hyperparathyroidism by vitamin D derivatives. Am J Kidney Dis 2001; 37(suppl 2): S58-S61.
11. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67:876-881.
12. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694-701.
13. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697-701.
14. Halliburton SS, Stillman AE, White RD. Noninvasive quantification of coronary artery calcification: methods and prognostic value. Cleve Clinic J Med 2002; 69(suppl 3): S-6-S-11.
15. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clinic J Med 2002; 69(suppl 3): S-12-S-20.
16. O'Rourke RA, Brundage BH, Froelich VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000; 102:126-140.
17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med 2000; 342:1478-1483.
18. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394-401.
19. Utsunomiya M. Angiographic study of calcification of coronary vessels in long term dialysis patients: examination of risk factors for coronary calcification. Nippon Jinzo Gakkai Shi 1996; 38:155-163.
20. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15:218-223.
21. Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001; 38:64-69.
22. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38(suppl 1):S34-S37.
23. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcifications in renal failure. J Am Soc Nephrol 2001; 12:2511-2516.
24. Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61:638-647.
25. Clarkson EM, Eastwood JB, Koutsaimainis KG, de Wardener HE. Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 1973; 3:258-263.
26. Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-dihydroxyvitamim D levels in subjects with renal disease. Kidney Int 1992; 41:161-165.